KR20240114794A - 신규 펩티드 - Google Patents

신규 펩티드 Download PDF

Info

Publication number
KR20240114794A
KR20240114794A KR1020247018934A KR20247018934A KR20240114794A KR 20240114794 A KR20240114794 A KR 20240114794A KR 1020247018934 A KR1020247018934 A KR 1020247018934A KR 20247018934 A KR20247018934 A KR 20247018934A KR 20240114794 A KR20240114794 A KR 20240114794A
Authority
KR
South Korea
Prior art keywords
seq
antibody
light chain
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018934A
Other languages
English (en)
Korean (ko)
Inventor
페터 엘마크
카린 헤거브란드
로라 바라스
마티아스 르빈
안나 셀
샨츠 로라 본
Original Assignee
엘리게이터 바이오사이언스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2204539.7A external-priority patent/GB202204539D0/en
Priority claimed from GBGB2212801.1A external-priority patent/GB202212801D0/en
Application filed by 엘리게이터 바이오사이언스 에이비 filed Critical 엘리게이터 바이오사이언스 에이비
Publication of KR20240114794A publication Critical patent/KR20240114794A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247018934A 2021-11-05 2022-11-04 신규 펩티드 Pending KR20240114794A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB202115925 2021-11-05
GB2115925.6 2021-11-05
GB2204539.7 2022-03-30
GBGB2204539.7A GB202204539D0 (en) 2022-03-30 2022-03-30 Novel peptides
GB2212801.1 2022-09-02
GBGB2212801.1A GB202212801D0 (en) 2022-09-02 2022-09-02 Novel peptides
PCT/EP2022/080861 WO2023079102A2 (en) 2021-11-05 2022-11-04 Novel peptides

Publications (1)

Publication Number Publication Date
KR20240114794A true KR20240114794A (ko) 2024-07-24

Family

ID=84329469

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247018934A Pending KR20240114794A (ko) 2021-11-05 2022-11-04 신규 펩티드
KR1020247018489A Pending KR20240099410A (ko) 2021-11-05 2022-11-04 신규한 폴리펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247018489A Pending KR20240099410A (ko) 2021-11-05 2022-11-04 신규한 폴리펩티드

Country Status (9)

Country Link
US (3) US11873348B2 (https=)
EP (2) EP4426738A2 (https=)
JP (2) JP2024543043A (https=)
KR (2) KR20240114794A (https=)
AU (1) AU2022381977A1 (https=)
CA (1) CA3237463A1 (https=)
IL (1) IL312556A (https=)
MX (1) MX2024005508A (https=)
WO (2) WO2023079102A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240114794A (ko) * 2021-11-05 2024-07-24 엘리게이터 바이오사이언스 에이비 신규 펩티드
WO2024213533A1 (en) * 2023-04-13 2024-10-17 Alligator Bioscience Ab Combination therapies
CN117924468B (zh) * 2023-12-08 2024-09-20 南京大学 一种靶向登革热病毒ns1蛋白纳米抗体的制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
GB201820556D0 (en) 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
CN113677703A (zh) * 2018-12-17 2021-11-19 鳄鱼生物科学公司 多肽
CN120383671A (zh) * 2019-09-30 2025-07-29 阿迪马布有限责任公司 被工程化用于优先轻链配对的ch1结构域变体和包括所述ch1结构域变体的多特异性抗体
KR20220103957A (ko) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체
MX2022008524A (es) * 2020-01-09 2022-09-21 Biomunex Pharmaceuticals Anticuerpos multiespecificos que se unen tanto a linfocitos mait como a celulas tumorales.
KR20240114794A (ko) * 2021-11-05 2024-07-24 엘리게이터 바이오사이언스 에이비 신규 펩티드

Also Published As

Publication number Publication date
EP4426733A2 (en) 2024-09-11
US20240117074A1 (en) 2024-04-11
WO2023079102A3 (en) 2023-06-15
CA3237463A1 (en) 2023-05-11
US12448465B2 (en) 2025-10-21
US20260001961A1 (en) 2026-01-01
MX2024005508A (es) 2024-09-18
JP2024542142A (ja) 2024-11-13
US20230312754A1 (en) 2023-10-05
WO2023079101A2 (en) 2023-05-11
WO2023079101A3 (en) 2023-06-15
WO2023079102A2 (en) 2023-05-11
JP2024543043A (ja) 2024-11-19
EP4426738A2 (en) 2024-09-11
KR20240099410A (ko) 2024-06-28
US11873348B2 (en) 2024-01-16
IL312556A (en) 2024-07-01
AU2022381977A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
AU2021202085B2 (en) Binding molecules that modulate a biological activity expressed by a cell
KR102426765B1 (ko) Cd137에 대한 신규한 이중특이성 폴리펩타이드
EP3277305B1 (en) Antigen binding molecules comprising a trimeric tnf family ligand
US11713356B2 (en) Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
EP3489256B1 (en) Antigen binding molecules comprising a tnf family ligand trimer
US20190016771A1 (en) Trimeric costimulatory tnf family ligand-containing antigen binding molecules
US20190161555A1 (en) Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen
KR20190086477A (ko) 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
KR20230104617A (ko) 항-덱틴-1 항체 및 이의 사용 방법
US12448465B2 (en) Peptides
TW201805306A (zh) 包含tnf家族配位三聚體及pd1結合部份之抗原結合分子
US20220073635A1 (en) Novel polypeptides
CN116390948A (zh) 双功能分子
US20220064325A1 (en) Novel polypeptides
CN118556080A (zh) 新型肽
WO2025237420A1 (en) Her2 targetting antibodies, chimeric antigen receptors, and uses thereof
WO2024213533A1 (en) Combination therapies
CN121605130A (zh) 靶向btn3a和pd-1/pd-l1抑制轴的双特异性抗体
CN119213034A (zh) 双功能蛋白质及其制剂和用途
IL303902A (en) MUCIN 1-specific polypeptide and its use
HK40097196A (zh) 新型抗cldn18抗体
CN118434768A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
HK40093420A (zh) 双功能分子
HK40041672B (zh) 新型抗cd39抗体
HK40009952B (zh) 调节细胞表达的生物活性的结合分子

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000